Study: Most oncology drugs approved in Japan based on surrogate endpoints do not undergo confirmatory trials

Regulatory NewsRegulatory NewsAsiaBiologics/ biosimilars/ vaccinesClinical TrialsPharmaceuticalsProduct Lifecycle